AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company's aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America.
| Website: | www.aveooncology.com |
| Email: | aveo@argotpartners.com |
| Main Phone: | +1 617 588-1960 |
| Address: | One Broadway |
| Address 2: | 14th Floor |
| State: | MA |
| City / Town: | Cambridge |
| Country: | US |
| Postal Code: | 02142 |
| Exchange: | NSC |
| CEO: | Michael P. Bailey |
| Employees: | 19 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Tivozanib showed 44% improvement in progression free survival and 26% reduction in risk of progression or death compared to sorafenib (Image: AVEO Pharmaceuticals)
It’s been a pretty wild year for the health care sector. Public attention was captured by the relatively disastrous rollout of Obamacare’s exchanges, and the plethora of opinions that
At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have
U.S. Retail Sales posted their largest gain in five months in February. Total retail sales increased 1.1% percent (after a 0.6% rise in January). According to ICSC-Goldman, the same-store sales
Investing in small-cap stocks can be a real crap shoot. While larger, blue-chips have a certain stability connected to their size, small-cap companies can experience much larger swings up and
The International trade balance rose to $48.8 billion in December. The Michigan Consumer Sentiment Survey came in weaker than expected at 72.5. The Dow Jones Industrial Average opened lower and
US stock futures point to a lower open Tuesday after poor growth figures emerge out of Europe. While all attention has been focused on the sovereign debt crisis, economic data has been in the
AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company's aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America.
| Website: | www.aveooncology.com |
| Email: | aveo@argotpartners.com |
| Main Phone: | +1 617 588-1960 |
| Address: | One Broadway |
| Address 2: | 14th Floor |
| State: | MA |
| City / Town: | Cambridge |
| Country: | US |
| Postal Code: | 02142 |
| Exchange: | NSC |
| CEO: | Michael P. Bailey |
| Employees: | 19 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Tivozanib showed 44% improvement in progression free survival and 26% reduction in risk of progression or death compared to sorafenib (Image: AVEO Pharmaceuticals)
It’s been a pretty wild year for the health care sector. Public attention was captured by the relatively disastrous rollout of Obamacare’s exchanges, and the plethora of opinions that
At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have
U.S. Retail Sales posted their largest gain in five months in February. Total retail sales increased 1.1% percent (after a 0.6% rise in January). According to ICSC-Goldman, the same-store sales
Investing in small-cap stocks can be a real crap shoot. While larger, blue-chips have a certain stability connected to their size, small-cap companies can experience much larger swings up and
The International trade balance rose to $48.8 billion in December. The Michigan Consumer Sentiment Survey came in weaker than expected at 72.5. The Dow Jones Industrial Average opened lower and
US stock futures point to a lower open Tuesday after poor growth figures emerge out of Europe. While all attention has been focused on the sovereign debt crisis, economic data has been in the
| Last Price 8.15 | Change $ -0.18 | Change % -2.16 | Tick N/A |
| Bid 8.15 | Bid Size 100.00 | Ask 8.32 | Ask Size 100.00 |
| Open 8.25 | High 8.52 | Low 7.99 | Prev Close 8.33 |
| Last Trade | Volume 607,904 | 52 Wk Hi 10.71 | 52 Wk Low 2.24 |
| Market Cap 234.8 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 28,809,249.00 | EPS (TTM) -1.58 | PE Ratio -5.40 | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 72 | 74 |
| Number of Buys | 72 | 72 |
| Number of Sells | 0 | 2 |
| Net Activity | 11057427 | 11005613 |
| Last 10 Buys | Shares |
|---|---|
| David M. Mott | 1,000 |
| Peter Sonsini | 1,000 |
| Jon Sakoda | 1,000 |
| Forest Baskett | 1,000 |
| Sandell D Scott | 1,000 |
| Anthony A. Florence | 1,000 |
| Peter J. Barris | 1,000 |
| Ravi Viswanathan | 1,000 |
| Joshua Makower | 1,000 |
| Ravi Viswanathan | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Matthew Dallas | 1,000 |
| Michael P. Bailey | 1,000 |
| Matthew Dallas | 1,000 |
| Joseph Vittiglio | 1,000 |
| Jeno Gyuris | 1,000 |
| Joseph Vittiglio | 1,000 |
| Jeno Gyuris | 1,000 |
| William Slichenmyer | 1,000 |
| Michael P. Bailey | 1,000 |
| David Johnston | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 7 | 7 | 7 | 7 |
| Low Target Price Estimate | 5 | 5 | 5 | 5 |
| Mean Target Price Estimate | 5.67 | 5.67 | 5.67 | 5.67 |
| Standard Deviation | 1.15 | 1.15 | 1.15 | 1.15 |
| Date of Most Recent Estimate | 05/08/18 | 05/08/18 | 05/08/18 | 05/08/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2021 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait